AndroGel maker AbbVie Inc. has reached a tentative agreement to settle about 6,000 lawsuits pending in a multidistrict litigation (MDL) alleging its testosterone replacement therapy causes heart attacks, strokes and blood clots. All cases against AbbVie and its subsidiaries Abbott Laboratories, Solvay Pharmaceuticals Inc., and Unimed Pharmaceuticals LLC, have been stayed per an order by U.S. District Judge Matthew Kennelly as the companies work toward finalizing a global settlement. The multidistrict litigation was centralized in the Northern District of Illinois in 2014 against several testosterone manufacturers, over claims that the companies hid cardiovascular side effects from consumers. Beginning in July ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.